TEST:

SPOT-MAS 10 Test

''This topic took center stage at the Gene Solutions Hong Kong’s Symposium during the Multi-specialty Medical Mega Conference (MMMC) 2026, under the track “AI in Healthcare: Applications and Evidence.” As one of the region’s largest multidisciplinary medical congresses, MMMC brought together more than 1,000 healthcare professionals across specialties for continuing medical education and professional exchange...Drawing on the latest global evidence and real-world experience, Dr. Brendan Chia Seng Hup, Senior Consultant and Director of Radiation Oncology at Raffles Hospital Singapore, delivered an insightful presentation titled “Next-Generation AI-Powered MCED Multi-omics Technology: Transforming Early Cancer Detection” on four key areas...Real-world evidence supporting MCED: Real‑world data and prospective studies, including K-DETEK, support the continued evaluation of technologies such as SPOT-MAS as a blood-based multi-cancer early detection approach.''

''Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster presentations, highlighting advances in integrated prenatal genomic screening and methylation-based gynecologic cancer risk assessment...At ISPD 2026, Gene Solutions will contribute to the scientific dialogue through a focused program of symposium discussions, scientific sessions, oral presentations, and virtual posters. Together, these contributions will spotlight two important directions in precision healthcare: next-generation non-invasive prenatal testing and methylation-based molecular triage for gynecologic cancers, anchored by innovations including triSure Procare, epiHERA®, and SPOT-MAS Eva.''

Gene Solutions Brazil and Bioma Genetics announced the introduction of SPOT-MAS in Brazil during an exclusive scientific event held in São Paulo, marking an important step in expanding access to innovative multi-cancer screening technologies across Latin America.

''Gene Solutions Malaysia, in collaboration with the National Cancer Society of Malaysia (NCSM), has expanded access to blood-based multi-cancer detection through the Early4Life initiative, reaching communities and frontline institutions across Malaysia with close to 300 SPOT-MAS 10 tests delivered to date.''

''Gene Solutions...today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi–omics blood test designed to detect cancer–associated signals.''

''Gene Solutions...Taiwan joins this movement with the introduction of SPOT-MAS – an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health. ''

"Gene Solutions...proudly announces a groundbreaking achievement in cancer early detection. The company's innovative SPOT-MAS test has become the first multi-cancer screening blood test in Asia to complete large prospective cohort validation, as published in BMC Medicine. This milestone marks a major advancement, enabling large-scale, non-invasive early detection."